This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPED2K1BI_M.jpg
According to BofA, the clear success of donanemab in Phase 3 will help to substantially diminish skepticism among physicians, payers, caregivers and patients, around the use of plaque removing antibodies. The firm believes the data reflects differences between the drugs and clinical trial populations that likely result in a split of an expanding market opportunity. But, overall, the firm thinks this data actually boosts the likelihood of a successful Leqembi launch.
Following the prolonged controversy surrounding Aduhelm, BofA believes that the success of lecanemab puts that story in the past. In the future, the firm expects that a second commercial effort in the space of Alzheimer, led by Eisai, will have a different outcome. The firm anticipates a quick approval from the FDA and a change at CMS on the reimbursement side opening up a much different commercial launch than it experienced for Aduhelm.
By Davit Kirakosyan
